CF Drug Kaftrio Cuts Insulin Needs by 19% in French Study

People living with both cystic fibrosis and diabetes just got encouraging news about managing their blood sugar with less medication.

A year-long French study found that adults with cystic fibrosis-related diabetes (CFRD) needed 19% less insulin after starting Kaftrio, a triple-combination drug that helps the body's faulty CFTR protein work better. Their blood sugar levels also became more stable, reducing dangerous dips and spikes.

The DIATRIM study tracked 107 adults across 13 French medical centers who had been living with CFRD for about 11 years. At the study's start, 65% were taking multiple daily insulin injections to manage their blood sugar.

After one year on Kaftrio, total daily insulin doses dropped from 0.37 to 0.30 units per kilogram of body weight. Mealtime insulin doses fell even more dramatically. About 6.5% of patients who had been using insulin were able to stop it completely.

Continuous glucose monitors revealed steadier blood sugar throughout the day, with less time spent dangerously low. This matters because blood sugar swings are common in CF-related diabetes and can cause serious complications.

The benefits extended beyond diabetes management. Patients gained weight and improved their BMI, suggesting better nutrition. Lung function jumped from 61.5% to 76.9% of predicted normal values. The need for intravenous antibiotics plummeted from 46% of patients to just 11%.

About half of people with cystic fibrosis develop diabetes because thick mucus damages the pancreas over time. This form of diabetes has been linked to worse lung function, lower body weight, and higher mortality risk.

Why This Inspires

Managing two complex conditions simultaneously creates enormous daily burden. Taking multiple insulin shots, monitoring blood sugar constantly, and dealing with CF treatments can be exhausting.

The possibility of reducing that burden while actually improving health outcomes represents real progress for a community that faces daily challenges. While researchers note that one measure of long-term blood sugar control (HbA1c) didn't change significantly, the combination of lower insulin needs, steadier glucose levels, and dramatic improvements in weight and lung function paints a hopeful picture.

For families navigating CF and diabetes together, this research suggests their treatment load could lighten as their health improves.